Cost-effectiveness of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China and the United States healthcare systems.
| Publicado en: | International Journal of Clinical Pharmacy Vol. 48; no. 4; pp. 1533 - 1548 |
|---|---|
| Autores principales: | , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Aug2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Descripción no disponible. |